LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome

American Journal of Clinical Pathology

Volumn 129, Issue 5, 2008, Pages 802-810

  Doi, Suhail A R ^a,b,c   Abbas, Jasem M K ^a   Parkinson, Lynne ^b   Chakraborty, Jagadish ^c   Akanji, Abayomi O ^c  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Atherogenic dyslipidemia; Coronary heart disease; Low density lipoprotein; Polycystic ovary syndrome; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PARTICLE SIZE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD; PATHOPHYSIOLOGY; ROC CURVE; ULTRASTRUCTURE;

ADOLESCENT; ADULT; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; DYSLIPIDEMIAS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; PARTICLE SIZE; POLYCYSTIC OVARY SYNDROME; ROC CURVE; TRIGLYCERIDES;

EID: 44849116357     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/E7EGTTVCRFVBA7EC     Document Type: Article

References (57)

1. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab. 2002;16:263-272.
2. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003;14:365-370.
3. Doi SA, Towers PA, Scott CJ, et al. PCOS: an ovarian disorder that leads to dysregulation in the hypothalamic-pituitary-adrenal axis? Eur J Obstet Gynecol Reprod Biol. 2005;118:4-16.
4. Sukalich S, Guzick D. Cardiovascular health in women with polycystic ovary syndrome. Semin Reprod Med. 2003;21:309-315.
5. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71:599-604.
6. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med. 1997;126:32-35.
7. Guzick DS, Talbott EO, Sutton-Tyrrell K, et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol. 1996;174:1224-1232.
8. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000;20:2414-2421.
9. Bickerton AS, Clark N, Meeking D, et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol. 2005;58:151-154.
10. Apridonidze T, Essah PA, Iuorno MJ, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929-1935.
11. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-1379.
12. Austin MA, Jarvik GP, Hokanson JE, et al. Complex segregation analysis of LDL peak particle diameter. Genet Epidemiol. 1993;10:599-604.
13. Hirany SV, Othman Y, Kutscher P, et al. Comparison of low-density lipoprotein size by polyacrylamide tube gel electrophoresis and polyacrylamide gradient gel electrophoresis. Am J Clin Pathol. 2003;119:439-445.
14. Tribble DL, Rizzo M, Chait A, et al. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med. 2001;110:103-110.
15. Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf). 2001;54:447-453.
16. Dejager S, Pichard C, Giral P, et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf). 2001;54:455-462.
17. Legro RS, Blanche P, Krauss RM, et al. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril. 1999;72:990-995.
18. Berneis K, Rizzo M, Lazzarini V, et al. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:186-189.
19. Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group. Revised. 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. January 2004;81:19-25.
20. Doi SA, Al-Zaid M, Towers PA, et al. Steroidogenic alterations and adrenal androgen excess in PCOS. Steroids. 2006;71:751-759.
21. Doi SA, Al-Zaid M, Towers PA, et al. Irregular cycles and steroid hormones in polycystic ovary syndrome. Hum Reprod. 2005;20:2402-2408.
22. Doi SA, Al-Zaid M, Towers PA, et al. Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome. J Endocrinol Invest. 2005;28:882-892.
23. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293:355-359.
24. Jahanfar S, Eden JA. Idiopathic hirsutism or polycystic ovary syndrome? Aust N Z J Obstet Gynaecol. 1993;33:414-416.
25. Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril. 1999;71:319-322.
26. Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. Am J Med. 2001;111:602-606.
27. Legro RS, Driscoll D, Strauss JF III, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998;95:14956-14960.
28. Escobar-Morreale HF, Serrano-Gotarredona J, Garcia-Robles R, et al. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist? Metabolism. 1997;46:902-907.
29. van Hooff MH, van der Meer M, Lambalk CB, et al. Variation of luteinizing hormone and androgens in oligomenorrhoea and its implications for the study of polycystic ovary syndrome. Hum Reprod. 1999;14:1684-1689.
30. Hirano T, Ito Y, Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb. 2005;12:67-72.
31. Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001;47:266-274.
32. Ensign W, Hill N, Heward CB. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem. 2006;52:1722-1727.
33. 2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51:2264-2273.
34. Kazumi T, Kawaguchi A, Hozumi T, et al. Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis. 1999;142:113-119.
35. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley; 2000.
36. Yilmaz M, Biri A, Bukan N, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol. 2005;20:258-263.
37. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
38. Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003;88:4525-4532.
39. Rizzo M, Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev. 2007;23:14-20.
40. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular prevention. Eur J Intern Med. 2006;17:77-80.
41. Rizzo M, Berneis K, Corrado E, et al. The significance of low-density-lipoproteins size in vascular diseases. Int Angiol. 2006;25:4-9.
42. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553-559.
43. Tarkun I, Arslan BC, Canturk Z, et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004;89:5592-5596.
44. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607-613.
45. Maitra A, Pingle RR, Menon PS, et al. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women. Int J Fertil Womens Med. 2001;46:271-277.
46. Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation. 1993;88:381-387.
47. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
48. Sniderman AD, Rosenbloom M. If ApoB is so good, why isn't everybody measuring it? one reason why we need The Netherlands Journal of Medicine! Neth J Med. 2005;63:232-235.
49. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
50. Guerin M, Le Goff W, Lassel TS, et al. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001;21:282-288.
51. Ikewaki K, Noma K, Tohyama J, et al. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia: a nuclear magnetic resonance study. Int J Cardiol. 2005;101:441-447.
52. Superko HR, Berneis KK, Williams PT, et al. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol. 2005;96:1266-1272.
53. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18:269-276.
54. Jonkers IJ, Smelt AH, van der Laarse A. Hypertriglyceridemia: associated risks and effect of drug treatment. Am J Cardiovasc Drugs. 2001;1:455-466.
55. Rajkhowa M, Neary RH, Kumpatla P, et al. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:3389-3394.
56. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987;113:589-597.
57. Kunz F, Pechlaner C, Erhart R, et al. HDL and plasma phospholipids in coronary artery disease. Arterioscler Thromb. 1994;14:1146-1150.